Pharmacodynamic Biomarkers in Model-Based Drug Development in Oncology

Publisher： Bentham Science Publishers

E-ISSN： 2212-3938|6|1|30-40

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.6, Iss.1, 2011-02, pp. : 30-40

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The current role of model-based drug development

By Suryawanshi Satyendra   Zhang Liping   Pfister Marc   Meibohm Bernd  

Expert Opinion on Drug Discovery, Vol. 5, Iss. 4, 2010-04 ,pp. : 311-321

Informa Healthcare

Access to resources Recommend Favorite

Biomarkers in oncology drug development: rescuers or troublemakers?

By Marrer Estelle   Dieterle Frank  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 11, 2008-11 ,pp. : 1391-1402

Informa Healthcare

Access to resources Recommend Favorite

Model‐Based Evaluation of Radiation and Radiosensitizing Agents in Oncology

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 7, Iss. 1, 2018-01 ,pp. : 51-58

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment

By Harrold John   Abraham Anson  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 41, Iss. 2, 2014-04 ,pp. : 141-151

Springer Publishing Company

Access to resources Recommend Favorite

Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity

By Nucci Gianluca   Gomeni Roberto   Poggesi Italo  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 8, 2009-08 ,pp. : 837-856

Informa Healthcare

Access to resources Recommend Favorite